BrainCells Inc. Appoints Philip Jochelson, M.D. Chief Medical Officer and Jason Levin...

BrainCells Inc. Appoints Philip Jochelson, M.D. Chief Medical Officer and
Jason Levin Chief Business Officer

SAN DIEGO, March 30 /PRNewswire/ -- BrainCells Inc. (BCI), a company leading
the scientific research of neurogenesis using its proprietary platform
technology to identify novel pathways for the treatment of neurologic
conditions, announced today the appointment of Dr. Philip Jochelson as chief
medical officer and Jason Levin as chief business officer. Both have extensive
experience in the biopharmaceutical industry with specific expertise in
building neurology assets for success. The two will serve in integral roles
managing clinical programs and licensing/partnership agreements for
BrainCells' pipeline of neurologic compounds.

"We have two compounds in Phase 2 trials which will produce the first ever
data on clinical impact from targeting neurogenesis for therapeutic benefit,"
said Jim Schoeneck, BrainCells CEO. "We have confidence in our drug candidates
based on what we know about their neurogenic properties from our platform that
enables us to conduct comparison analysis between multiple compounds,
experiment with various pathways, analyze complex pharmacology, and image and
measure the neurogenic process. Philip and Jason are top caliber people that
come at a pivotal time in the company's development."

Dr. Jochelson will replace Steve Targum as chief medical officer. His primary
focus will be on progression of the company's clinical programs and expansion
of the pipeline into broader indications. Dr. Jochelson was most recently
senior vice president of development and chief medical officer at Somaxon, a
neurology and psychiatry-focused specialty pharmaceutical company, where he
was responsible for the development of all product candidates while also
supporting financing and business development activities. Prior to that, he
was at Neurocrine Biosciences where he led several clinical development
programs. Through his combined experience, he has designed and implemented
multiple clinical studies across all phases of development, and has progressed
three compounds from Phase 1 to NDA submission. Dr. Jochelson previously held
positions in clinical development at Boehringer Ingelheim and Alliance
Pharmaceutical Corp. He graduated from Medical School in South Africa and is a
licensed physician in California.

Mr. Levin will be responsible for all strategic business development
activities including licensing, acquisitions and partnering. He joins
BrainCells with more than 15 years of experience in the life science industry,
most recently as vice president of corporate development at Jazz
Pharmaceuticals, a neurology and psychiatry-focused specialty pharmaceutical
company, where he was responsible for licensing, acquisitions, corporate
strategy and strategic alliances. Prior to Jazz Pharmaceuticals, he was
director of business development at ALZA Corporation, a wholly owned
subsidiary of Johnson and Johnson, where he was responsible for both in- and
out-licensing of the company's drug delivery technology. Mr. Levin received an
M.B.A. from the University of Texas, McCombs Graduate School of Business, has
been a member of the Licensing Executive Society since 2000 and serves as an
advisor to several early stage biopharmaceutical companies.

About BrainCells Inc.
BrainCells Inc. (BCI) is a drug discovery and development company leading the
scientific research of neurogenesis by applying its robust and proprietary
platform technology to identify novel pathways for small molecule therapeutics
to treat various neurologic conditions. Neurogenesis is the process by which
endogenous stem cells in the adult human brain produce new brain tissue,
including neurons. With its predictive screening platform, BCI can direct the
selection and development of neurogenic compounds, increasing the opportunity
for successful clinical trials in a variety of neurological indications. For
more information, visit http://www.braincellsinc.com.

Contact:
Kim Richards
Porter Novelli Life Sciences
619-849-5377
krichards@pnlifesciences.com

SOURCE BrainCells Inc.

Kim Richards of Porter Novelli Life Sciences, +1-619-849-5377,
krichards@pnlifesciences.com, for BrainCells Inc.